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Summary
Objectives: To identify the risk factors for nosocomial imipenem-resistant Acinetobacter bau-
mannii (IRAB) infections.
Methods: A prospective case—control study, set in an 1100-bed referral and tertiary-care
hospital, of all patients who had nosocomial A. baumannii infections between January 1 and
December 31, 2004. Only the first isolation of A. baumannii was considered.
Results: IRAB was isolated from 66 (53.7%) patients and imipenem-sensitive Acinetobacter
baumannii (ISAB) was isolated from 57 (46.3%) patients during the study period. The mean
duration of hospital stay until A. baumannii isolation was 20.8  13.6 days in IRAB infections,
whereas it was 15.4  9.4 days in ISAB infections. Of the patients, 65.2% with IRAB infections and
40.4% with ISAB infections were followed at the intensive care unit (ICU). Previous carbapenem
use was present in 43.9% of the patients with IRAB and 12.3% of the patients with ISAB infection. In
univariate analysis female sex, longer duration of hospital stay until infection, ICU stay, emergent
surgical operation, total parenteral nutrition, having a central venous catheter, endotracheal
tube, urinary catheter or nasogastric tube, previous antibiotic use, and previous administration of
carbapenems were significant risk factors for IRAB infections ( p < 0.05). In multivariate analysis,
longer duration of hospital stay until A. baumannii isolation (odds ratio (OR) 1.043; 95%
confidence interval (CI) 1.003—1.084; p = 0.032), previous antibiotic use (OR 5.051; 95% CI
1.004—25.396; p = 0.049), and ICU stay (OR 3.100; 95% CI 1.398—6.873; p = 0.005) were inde-
pendently associated with imipenem resistance.
Conclusions: Our results suggest that the nosocomial occurrence of IRAB is strongly related to an
ICU stay and duration of hospital stay, and that IRAB occurrence may be favored by the selection
pressure of previously used antibiotics.
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Acinetobacter baumannii is an important cause of nosoco-
mial infections in many hospitals, which is difficult to both
control and treat because of its prolonged environmental
survival and its ability to develop resistance to multiple
antimicrobial agents.1,2 Acinetobacter baumannii appears
to have a propensity for developing antimicrobial resistance
extremely rapidly. Moreover this resistance is multiple, caus-
ing serious therapeutic problems.1 Carbapenems are usually
the antibiotics of choice for treating serious infections
caused by A. baumannii. However, reports of imipenem-
resistant A. baumannii (IRAB) strains have been rising stea-
dily during the past few years, and these isolates are often
multidrug-resistant.3—6 This emergence of IRAB has become a
worldwide problem and a troublesome development that
threatens the continued successful treatment of Acinetobac-
ter infections.1,7
More data regarding the risk factors for IRAB infection are
needed in order to prevent infection and to optimize therapy.
Previous studies of risk factors for IRAB have focused on an
outbreak or colonized/infected patients evaluated together.
Acinetobacter baumannii is frequently encountered in Turk-
ish hospitals, and many isolates exhibit resistance to the
antimicrobials commonly used against such bacterial infec-
tions. The present study investigated the risk factors for
nosocomial IRAB infections.
Methods
The hospital setting and study population
A prospective case—control study was performed at Ankara
Numune Education and Research Hospital (ANERH) in Turkey.
ANERH is an 1100-bed referral and tertiary-care hospital. The
hospital provides all major services except a pediatric
department, including medical and surgical sub-specialties,
and medical and surgical intensive care units (ICUs). The
annual number of discharges was 55 422 in 2004.
Antibiotic policy
An antibiotic restriction policy has been in effect at ANERH
since January 1999. The restriction is for orders of certain
antibiotics; a prior consultation with an infectious diseases
(ID) specialist is required for ceftazidime, cefepime,
imipenem, meropenem, ticarcillin—clavulanate, piperacil-
lin—tazobactam, cefoperazone—sulbactam, intravenous
quinolones, intravenous aminoglycosides, vancomycin,
and teicoplanin.
Case definition and collection of data
Prospective surveillance was conducted. Patients who had A.
baumannii infections from January to December 2004 were
included in the study. Patients from whom A. baumannii
isolates had been recovered within 48 h of admission and
those younger than 16 years of age were excluded.
Only one isolate from each patient was included (only the
first A. baumannii-positive specimen). The clinical signifi-
cance (colonization or infection) of each A. baumannii isolateand the type of infection were assessed according to CDC
criteria8,9 by infectious diseases specialists. A urinary tract
infection in a patient with an indwelling bladder catheter was
diagnosed with detection of pyuria (10 leukocytes/mm3),
growth of 105 CFU/ml bacteria (no more than two species)
in urine culture, and clinical signs of infection (fever 38 8C,
leukocytosis, abnormal macroscopic appearance of urine,
presence of urinary nitrites). In patients assisted by mechan-
ical ventilation, pneumonia was diagnosed when a new or
progressive infiltrate or consolidation in chest X-ray in the
presence of purulent tracheal secretions, supported by a
growth of 105 CFU/ml bacteria in a quantitative culture
of deep endotracheal aspirate was found. For non-ventilated
patients, the diagnosis of nosocomial pneumonia was con-
sidered when they had a compatible chest X-ray and purulent
sputum, with Gram stain and sputum culture documenting
the presence of a pathogen microorganism. Surgical site
infection was defined as the presence of purulent drainage
and positive clinical findings (incision site pain, tenderness,
localized swelling, redness or heat, spontaneous opening of
the incision) supported by microbiologic analysis of speci-
mens. Sepsis was diagnosed by the presence of the sepsis
criteria and positive blood cultures. Patients colonized with
A. baumannii were excluded.
Data were recorded on individual forms for each patient.
The form included age, sex, diagnosis, date of admission to
hospital and ICU, hospitalization period before ICU, length of
hospital and ICU stay, transfer from another hospital, comor-
bidity (renal failure, hepatic failure, malignancy, immuno-
suppression, diabetes mellitus, chronic lung disease,
malnutrition, transplantation), elective or emergent surgical
operations, APACHE II (acute physiological and chronic health
evaluation) score, ventilator support, physical examination
findings, hematological and biochemical test results, anti-
biotics given to the patient, culture and antimicrobial sus-
ceptibility test results, and time between admission and
isolation of the first positive A. baumannii culture.
Prior exposures to antimicrobial drugs were also explored.
Prior antibiotic exposures were defined as at least 24 h of
therapy during the 14 days prior to isolation of the A.
baumannii.
The patients were assigned as IRAB cases (case patients) if
they had imipenem-resistant A. baumannii infections and as
ISAB cases (control patients) if they had imipenem-sensitive
A. baumannii infections.
Microbiological examination
Identification and antimicrobial susceptibility of the Gram-
negative bacteria isolated from ICU-acquired infections were
performed by VITEK automated system (BioMerieux). The
GNI+ panel was used for identification and GN528 panel for
the detection of antimicrobial susceptibility. The isolates
with a minimum inhibitory concentration (MIC) value
8 mg/ml were recorded as imipenem-resistant and those
with a MIC value <8 mg/ml as imipenem-sensitive. All of the
strains were tested against the following antibiotics: amika-
cin, gentamicin, aztreonam, ceftazidime, cefepime, imipe-
nem, netilmicin, ciprofloxacin, pefloxacin, piperacillin,
piperacillin—tazobactam, ticarcillin, ticarcillin—clavula-
nate, and trimethoprim—sulfamethoxazole. Intermediately
susceptible strains were accepted as resistant.
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Table 1 Nosocomial infection sites of imipenem-sensitive A. baumannii (ISAB) and imipenem-resistant A. baumannii (IRAB)
Infection ISAB (N = 57) n (%) IRAB (N = 66) n (%) Total (N = 123) n (%) p
Surgical site infection 19 (33.3) 19 (28.8) 38 (30.9) 0.586
Blood stream infection 18 (31.6) 15 (22.7) 33 (26.8) 0.269
Pneumonia 12 (21.1) 20 (30.3) 32 (26.0) 0.243
Urinary tract infection 8 (14.0) 12 (18.2) 20 (16.3) 0.534
Total 57 (100) 66 (100) 123 (100)Statistical analysis
Potential risk factors were analyzed by univariate and multi-
variate analysis. Results are expressed as mean  SD unless
otherwise indicated. The Student’s t-test for independent
and paired continuous variables and the Chi-square test or
Fisher’s exact test were used when appropriate to compare
proportions. A p-value of <0.05 was considered statistically
significant. To test the independence of the risk factors for
imipenem resistance, the significant variables ( p < 0.05) in
the univariate analyses were entered into a multivariate
logistic regression model with backward selection of inde-
pendent variables. Risk factors were checked for confound-
ing and co-linearity. The software package STATA 7.0 (College
station, Texas, USA) was used for the analysis.
Results
During the study period, A. baumannii infections were
detected in 123 patients. Mean age was 47.9  19 (range
16—90) and 83 (67.5%) were male. ICU patients accounted for
66 (53.7%) of the infected patients. The most frequent
infection was SSI (30.9%), followed by blood stream infection
(26.8%), pneumonia (26.0%), and urinary tract infection
(16.3%).
Of the 123 patients, 66 (53.7%) had IRAB and 57 (46.3%)
had ISAB infections. The most frequent types of infections
were pneumonia (30.3%) and SSI (28.8%) with IRAB, whereas
with ISAB they were SSI (33.3%) and blood stream infection
(31.6%) (Table 1). No statistically significant difference was
found between the infection sites caused by IRAB and ISAB
( p > 0.05).
The mean duration of hospital stay until A. baumannii
isolation was 20.8  13.6 days in IRAB infections, whereas it
was 15.4  9.4 days in ISAB infections ( p = 0.014). Of the
patients, 65.2% with an IRAB infection and 40.4% with an ISAB
infection were followed at the ICU.
IRAB infections were seen more frequently in ICUs than
wards (65.2% and 34.8%, respectively, p = 0.006). The med-
ical or surgical services from which patients with IRAB and
ISAB infections were receiving care included medical wards
(26% and 29.5%, respectively) and surgical wards (73.9 and
70.5, respectively; p = 0.784).
Results of the univariate analysis of risk factors for IRAB
are outlined in Table 2. Female sex, longer duration of
hospital stay until infection, ICU stay, emergent surgical
operation, total parenteral nutrition, having a central venous
catheter, endotracheal tube, urinary catheter, or nasogastric
tube, previous antibiotic use, and previous administration of
carbapenems were significant risk factors for IRAB infections
( p < 0.05).In multivariate analysis, longer duration of hospital stay
until A. baumannii isolation (odds ratio (OR) 1.043; 95%
confidence interval (CI) 1.003—1.084; p = 0.032), previous
antibiotic use (OR 5.051; 95% CI 1.004—25.396; p = 0.049),
and ICU stay (OR 3.100; 95% CI 1.398—6.873; p = 0.005) were
independently associated with imipenem resistance
(Table 3).
The resistance rates of IRAB isolates to the other anti-
biotics were frequently higher than those of ISAB isolates
(Table 4).
There was no outbreak due to A. baumannii during the
study period.
Discussion
Various studies have reported that the incidence of imipenem
resistance in Acinetobacter spp is 6—8% in the USA and
Canada, 10% in Latin America, and 16% in Europe.10—12 The
overall incidence of IRAB infection/colonization in Spain is
quite high at 1.36 cases/1000 hospital admissions.2 Although
there are no similar published studies with which to compare
the incidence of patients with IRAB infection, in this study the
frequency of IRAB infections was 1.2 cases/1000 hospital
admissions, and among the Acinetobacter infections imipe-
nem resistance was observed in 53.7%. This study assessed
the risk factors for the development of IRAB infections,
whereas previous studies have focused on an outbreak or
colonized/infected patients have been evaluated
together.2,3,13 A few analyses on the risk factors for the
acquisition of IRAB have been published.2,13 These studies
have limitations as colonized patients were also enrolled.
In clinical practice, Acinetobacter infections are closely
associated with surgery or the use of artificial devices.
Patients become infected following initial colonization. This
process is influenced by various risk factors, particularly in
ICUs, where multiple manipulations following surgery, as well
as the use of endotracheal tubes and intravascular, ventri-
cular or urinary catheters, can result in colonization by
opportunistic bacteria such as Acinetobacter. The presence
and duration of invasive procedures, as well as exposure to
broad-spectrum antibiotics have been identified as risk fac-
tors for acquisition of Acinetobacter in numerous studies.14
In this study, it was found that longer duration of hospital
stay until A. baumannii isolation, ICU admission, emergent
surgical operation, total parenteral nutrition, invasive pro-
cedures such as central venous catheter, endotracheal tube,
urinary catheter, or nasogastric tube, previous antibiotic use,
and previous administration of carbapenems were significant
risk factors for IRAB infections ( p < 0.05). Multivariate ana-
lysis showed that longer duration of hospital stay until A.
baumannii isolation (OR 1.043; 95% CI 1.003—1.084;
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Table 2 Univariate analysis of risk factors for imipenem-resistant A. baumannii (IRAB) infections
Risk factors ISAB (N = 57) n (%) IRAB (N = 66) n (%) p
Age (mean) 47 48.7 0.623
Female sex 13 (22.8) 27 (40.9) 0.033
Comorbidity 21 (36.8) 31 (47.0) 0.257
Hospital stay until infection (days) 15.4  9.4 20.8  13.6 0.014
ICU stay 23 (40.4) 43 (65.2) 0.006
Surgery 27 (47.4) 35 (53.0) 0.531
Emergent surgery 8 (29.6) 20 (57.1) 0.031
Total parenteral nutrition 18 (31.6) 33 (50.0) 0.039
Enteral nutrition 8 (14.0) 15 (22.7) 0.218
Tracheostomy 6 (10.5) 12 (18.2) 0.231
Endotracheal tube 16 (28.1) 31 (47.0) 0.031
Central venous catheter 19 (33.3) 37 (56.1) 0.012
Urinary catheter 35 (61.4) 55 (83.3) 0.006
Surgical drain 4 (7.0) 12 (18.2) 0.066
Arterial line 17 (29.8) 31 (47.0) 0.052
Hemodialysis catheter 6 (10.5) 4 (6.1) 0.366
Nasogastric tube 17 (29.8) 34 (51.5) 0.015
Previous antibiotic use 46 (80.7) 64 (97.0) 0.003
Use of carbapenems 7 (12.3) 29 (43.9) <0.001
Use of ampicillin—sulbactam 8 (14.0) 4 (6.1) 0.119
Use of first-generation cephalosporins 7 (12.3) 2 (3.0) 0.052
Use of third-generation cephalosporins 9 (15.8) 10 (15.2) 0.922
Use of aminoglycosides 15 (26.3) 12 (18.2) 0.277
Use of glycopeptides 17 (29.8) 31 (47.0) 0.052
Use of piperacillin—tazobactam 11 (19.3) 13 (19.7) 0.956
Use of quinolones 6 (10.5) 7 (10.6) 0.989p = 0.032), previous antibiotic use (OR 5.051; 95% CI 1.004—
25.396; p = 0.049), and ICU stay (OR 3.100; 95% CI 1.398—
6.873; p = 0.005) were independently associated with imipe-
nem resistance. The risk of IRAB infections was three times
higher for patients who stayed in the ICU. The identification
of an ICU stay as a risk factor is not unexpected. It has also
been reported in the acquisition of IRAB in other studies.13 A
longer stay has been identified as a risk factor in previous
studies similar to our results.3,15,16
Antibiotic exposure remains one of the most important
risk factors for the acquisition of IRAB.15 According to our
results the previous use of carbapenems was associated with
imipenem resistance. The risk for imipenem resistance was
five-fold higher in patients who received previous antibiotic
therapy. In the study of Scerpella et al., third-generation
cephalosporins were associated with the acquisition of multi-
resistant A. baumannii in a nosocomial outbreak.16 del Mar
Tomas et al. reported that administration of imipenem as
monotherapy was a risk factor for colonization/infection
with carbapenem-resistant A. baumannii in a outbreak.3Table 3 Multivariate analysis (logistic regression) of risk factors
Independent risk factors Odds ratio
Hospital stay until infection 1.043
Previous antibiotic use 5.051
ICU stay 3.100On the other hand Smolyakov et al., found that prior ami-
noglycoside therapy and ICU admission were independently
associated with multidrug-resistant A. baumannii acquisi-
tion.17 Lee et al. suggested that prior exposure to imipenem
or third-generation cephalosporins were risk factors for the
nosocomial occurrence of IRAB.13
Acinetobacter spp have become resistant to almost all
antimicrobial agents that are currently available, including
the aminoglycosides, quinolones and broad-spectrum b-lac-
tams. Most strains are resistant to cephalosporins, while
resistance to carbapenems is being reported increas-
ingly.18,19 Important differences in antimicrobial susceptibil-
ity exist between A. baumannii and other species in the
genus, with A. baumannii being the most resistant spe-
cies.20,21
Among the 490 A. baumannii isolates from patients with
serious infections in 37 European hospitals participating in
the 1997—2000 MYSTIC program, the two carbapenems
showed the greatest clinically useful activity. Susceptibilities
of A. baumannii to meropenem were very high (97—100%) infor imipenem-resistant A. baumannii (IRAB) infections
95% Confidence interval (CI) p
1.003—1.084 0.032
1.004—25.396 0.049
1.398—6.873 0.005
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Table 4 Antimicrobial resistance rates of imipenem-sensitive A. baumannii (ISAB) and imipenem-resistant A. baumannii (IRAB)
isolates to the other antibiotics
Antibiotics ISAB (N = 57) n (%) IRAB (N = 66) n (%) p
Amikacin 31 (54.4) 57 (86.4) <0.001
Aztreonam 52 (91.2) 65 (98.5) 0.062
Cefepime 40 (70.2) 49 (74.2) 0.615
Ceftazidime 48 (84.2) 60 (90.9) 0.258
Ciprofloxacin 38 (66.7) 55 (83.3) 0.032
Gentamicin 42 (73.7) 52 (78.8) 0.506
Netilmicin 21 (36.8) 41 (62.1) 0.005
Pefloxacin 43 (75.4) 61 (92.4) 0.009
Piperacillin 46 (80.7) 66 (100) <0.001
Piperacillin—tazobactam 39 (68.4) 61 (92.4) 0.001
Ticarcillin 34 (59.6) 61 (92.4) <0.001
Ticarcillin clavulanate 23 (40.4) 58 (87.9) <0.001
Tobramycin 20 (35.1) 49 (74.2) <0.001
Trimethoprim—sulfamethoxazole 34 (59.6) 56 (84.8) 0.002all countries except Italy (70%), Turkey (66%), and the UK
(77%). A similar pattern was seen for imipenem (93—100%),
except for Italy (78%), Turkey (62%), and the UK (78%).12
Imipenem resistance, which was observed in 53.7% in this
study, was higher than in previous reports from Turkey; this
may be due to assessing only A. baumannii strains that were
responsible for nosocomial infections.
IRAB is one of the most difficult pathogens to treat,
because most of the patients with IRAB infections are criti-
cally ill and are subject to invasive life support measures such
as endotracheal tubes, central venous catheters, and urinary
catheters. Also, the isolates of IRAB are often multidrug-
resistant. The development of resistance to antimicrobials in
A. baumannii appears to be unstoppable.1 Twelve of the A.
baumannii isolates (9.8%) were resistant to all tested anti-
biotics in this study. Therapy of these infections is often
difficult. Sulbactam, colistin and polymyxins may be effec-
tive in such multidrug-resistant infections.22,23
In conclusion, our results suggest that the nosocomial
occurrence of IRAB infections are strongly related to an
ICU stay and duration of hospital stay, and that IRAB occur-
rence may be favored by the selection pressure of previously
used antibiotics.
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